Releases
Corporate Releases, Press Releases, and Features
Stay updated on Lundbeck’s latest company announcements. Subscribe to our releases.
LATEST RELEASES
- Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024
- Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention
- Capital Markets Event 2024: Lundbeck to showcase progress on Focused Innovator Strategy driving sustainable long-term growth
- Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline
- Lundbeck initiates clinical trial in immunology for Lu AG22515 in Thyroid Eye Disease
In order to comply with applicable regulation, press releases concerning a specific medicinal product are removed from our website within three weeks of publication. They can be retained upon request.
More from Lundbeck
Investor Relations
Detailed information related to Lundbeck’s financial performance. Contact Palle Olesen, VP Investor Relations. + 45 3083 2426
About Us
A global pharmaceutical company specialized in brain diseases.
Press
Lundbeck seeks an open dialogue with the press. For general press enquiries, please call + 45 3643 4000